Brief Report: CD4+ T Cells From Patients With Systemic Lupus Erythematosus Respond Poorly to Exogenous Interleukin‐2
Objective Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus‐prone mice and contributes to immune dysregulation. This study was undertaken to further investigate in detail the production of interleukin‐2 (IL‐2), interferon‐γ (IFNγ)...
Saved in:
Published in | Arthritis & rheumatology (Hoboken, N.J.) Vol. 69; no. 4; pp. 808 - 813 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.04.2017
|
Subjects | |
Online Access | Get full text |
ISSN | 2326-5191 2326-5205 2326-5205 |
DOI | 10.1002/art.40014 |
Cover
Abstract | Objective
Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus‐prone mice and contributes to immune dysregulation. This study was undertaken to further investigate in detail the production of interleukin‐2 (IL‐2), interferon‐γ (IFNγ), IL‐4, and IL‐17A by CD4+ cell subsets in healthy subjects and patients with SLE, and the signaling response of CD4+ T cells in response to exogenous IL‐2.
Methods
Cytokine production by differentiated subsets of CD4+ T cells was assessed by intracellular staining following stimulation with phorbol myristate acetate and ionomycin and by enzyme‐linked immunosorbent assay after anti‐CD3/anti‐CD28 stimulation. The IL‐2 signaling pathway was examined by assessing JAK‐3/STAT‐5 phosphorylation. Cell proliferation in response to IL‐2 was examined by carboxyfluorescein succinimidyl ester dilution.
Results
Production of IL‐2 was defective primarily among naive CD4+ T cells, whereas the production of IFNγ, IL‐4, and IL‐17A was not significantly different between patients with SLE and healthy subjects. JAK‐3/STAT‐5 phosphorylation and proliferation of CD4+ T cells from SLE patients in response to exogenous IL‐2 were impaired compared to cells from healthy subjects.
Conclusion
These data suggest that altered IL‐2 production, as well as impaired IL‐2–mediated signaling and proliferative responses, characterize SLE CD4+ T cells. Our data demonstrate the need for caution in designing IL‐2 treatment trials for patients with SLE. Approaches to restore CD4+ T cell sensitivity to IL‐2 should be considered. |
---|---|
AbstractList | ObjectiveImbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus‐prone mice and contributes to immune dysregulation. This study was undertaken to further investigate in detail the production of interleukin‐2 (IL‐2), interferon‐γ (IFNγ), IL‐4, and IL‐17A by CD4+ cell subsets in healthy subjects and patients with SLE, and the signaling response of CD4+ T cells in response to exogenous IL‐2.MethodsCytokine production by differentiated subsets of CD4+ T cells was assessed by intracellular staining following stimulation with phorbol myristate acetate and ionomycin and by enzyme‐linked immunosorbent assay after anti‐CD3/anti‐CD28 stimulation. The IL‐2 signaling pathway was examined by assessing JAK‐3/STAT‐5 phosphorylation. Cell proliferation in response to IL‐2 was examined by carboxyfluorescein succinimidyl ester dilution.ResultsProduction of IL‐2 was defective primarily among naive CD4+ T cells, whereas the production of IFNγ, IL‐4, and IL‐17A was not significantly different between patients with SLE and healthy subjects. JAK‐3/STAT‐5 phosphorylation and proliferation of CD4+ T cells from SLE patients in response to exogenous IL‐2 were impaired compared to cells from healthy subjects.ConclusionThese data suggest that altered IL‐2 production, as well as impaired IL‐2–mediated signaling and proliferative responses, characterize SLE CD4+ T cells. Our data demonstrate the need for caution in designing IL‐2 treatment trials for patients with SLE. Approaches to restore CD4+ T cell sensitivity to IL‐2 should be considered. Objective Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus-prone mice and contributes to immune dysregulation. This study was undertaken to further investigate in detail the production of interleukin-2 (IL-2), interferon- gamma (IFN gamma ), IL-4, and IL-17A by CD4+ cell subsets in healthy subjects and patients with SLE, and the signaling response of CD4+ T cells in response to exogenous IL-2. Methods Cytokine production by differentiated subsets of CD4+ T cells was assessed by intracellular staining following stimulation with phorbol myristate acetate and ionomycin and by enzyme-linked immunosorbent assay after anti-CD3/anti-CD28 stimulation. The IL-2 signaling pathway was examined by assessing JAK-3/STAT-5 phosphorylation. Cell proliferation in response to IL-2 was examined by carboxyfluorescein succinimidyl ester dilution. Results Production of IL-2 was defective primarily among naive CD4+ T cells, whereas the production of IFN gamma , IL-4, and IL-17A was not significantly different between patients with SLE and healthy subjects. JAK-3/STAT-5 phosphorylation and proliferation of CD4+ T cells from SLE patients in response to exogenous IL-2 were impaired compared to cells from healthy subjects. Conclusion These data suggest that altered IL-2 production, as well as impaired IL-2-mediated signaling and proliferative responses, characterize SLE CD4+ T cells. Our data demonstrate the need for caution in designing IL-2 treatment trials for patients with SLE. Approaches to restore CD4+ T cell sensitivity to IL-2 should be considered. Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus-prone mice and contributes to immune dysregulation. This study was undertaken to further investigate in detail the production of interleukin-2 (IL-2), interferon-γ (IFNγ), IL-4, and IL-17A by CD4+ cell subsets in healthy subjects and patients with SLE, and the signaling response of CD4+ T cells in response to exogenous IL-2. Cytokine production by differentiated subsets of CD4+ T cells was assessed by intracellular staining following stimulation with phorbol myristate acetate and ionomycin and by enzyme-linked immunosorbent assay after anti-CD3/anti-CD28 stimulation. The IL-2 signaling pathway was examined by assessing JAK-3/STAT-5 phosphorylation. Cell proliferation in response to IL-2 was examined by carboxyfluorescein succinimidyl ester dilution. Production of IL-2 was defective primarily among naive CD4+ T cells, whereas the production of IFNγ, IL-4, and IL-17A was not significantly different between patients with SLE and healthy subjects. JAK-3/STAT-5 phosphorylation and proliferation of CD4+ T cells from SLE patients in response to exogenous IL-2 were impaired compared to cells from healthy subjects. These data suggest that altered IL-2 production, as well as impaired IL-2-mediated signaling and proliferative responses, characterize SLE CD4+ T cells. Our data demonstrate the need for caution in designing IL-2 treatment trials for patients with SLE. Approaches to restore CD4+ T cell sensitivity to IL-2 should be considered. Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus-prone mice and contributes to immune dysregulation. This study was undertaken to further investigate in detail the production of interleukin-2 (IL-2), interferon-γ (IFNγ), IL-4, and IL-17A by CD4+ cell subsets in healthy subjects and patients with SLE, and the signaling response of CD4+ T cells in response to exogenous IL-2.OBJECTIVEImbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus-prone mice and contributes to immune dysregulation. This study was undertaken to further investigate in detail the production of interleukin-2 (IL-2), interferon-γ (IFNγ), IL-4, and IL-17A by CD4+ cell subsets in healthy subjects and patients with SLE, and the signaling response of CD4+ T cells in response to exogenous IL-2.Cytokine production by differentiated subsets of CD4+ T cells was assessed by intracellular staining following stimulation with phorbol myristate acetate and ionomycin and by enzyme-linked immunosorbent assay after anti-CD3/anti-CD28 stimulation. The IL-2 signaling pathway was examined by assessing JAK-3/STAT-5 phosphorylation. Cell proliferation in response to IL-2 was examined by carboxyfluorescein succinimidyl ester dilution.METHODSCytokine production by differentiated subsets of CD4+ T cells was assessed by intracellular staining following stimulation with phorbol myristate acetate and ionomycin and by enzyme-linked immunosorbent assay after anti-CD3/anti-CD28 stimulation. The IL-2 signaling pathway was examined by assessing JAK-3/STAT-5 phosphorylation. Cell proliferation in response to IL-2 was examined by carboxyfluorescein succinimidyl ester dilution.Production of IL-2 was defective primarily among naive CD4+ T cells, whereas the production of IFNγ, IL-4, and IL-17A was not significantly different between patients with SLE and healthy subjects. JAK-3/STAT-5 phosphorylation and proliferation of CD4+ T cells from SLE patients in response to exogenous IL-2 were impaired compared to cells from healthy subjects.RESULTSProduction of IL-2 was defective primarily among naive CD4+ T cells, whereas the production of IFNγ, IL-4, and IL-17A was not significantly different between patients with SLE and healthy subjects. JAK-3/STAT-5 phosphorylation and proliferation of CD4+ T cells from SLE patients in response to exogenous IL-2 were impaired compared to cells from healthy subjects.These data suggest that altered IL-2 production, as well as impaired IL-2-mediated signaling and proliferative responses, characterize SLE CD4+ T cells. Our data demonstrate the need for caution in designing IL-2 treatment trials for patients with SLE. Approaches to restore CD4+ T cell sensitivity to IL-2 should be considered.CONCLUSIONThese data suggest that altered IL-2 production, as well as impaired IL-2-mediated signaling and proliferative responses, characterize SLE CD4+ T cells. Our data demonstrate the need for caution in designing IL-2 treatment trials for patients with SLE. Approaches to restore CD4+ T cell sensitivity to IL-2 should be considered. Objective Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus‐prone mice and contributes to immune dysregulation. This study was undertaken to further investigate in detail the production of interleukin‐2 (IL‐2), interferon‐γ (IFNγ), IL‐4, and IL‐17A by CD4+ cell subsets in healthy subjects and patients with SLE, and the signaling response of CD4+ T cells in response to exogenous IL‐2. Methods Cytokine production by differentiated subsets of CD4+ T cells was assessed by intracellular staining following stimulation with phorbol myristate acetate and ionomycin and by enzyme‐linked immunosorbent assay after anti‐CD3/anti‐CD28 stimulation. The IL‐2 signaling pathway was examined by assessing JAK‐3/STAT‐5 phosphorylation. Cell proliferation in response to IL‐2 was examined by carboxyfluorescein succinimidyl ester dilution. Results Production of IL‐2 was defective primarily among naive CD4+ T cells, whereas the production of IFNγ, IL‐4, and IL‐17A was not significantly different between patients with SLE and healthy subjects. JAK‐3/STAT‐5 phosphorylation and proliferation of CD4+ T cells from SLE patients in response to exogenous IL‐2 were impaired compared to cells from healthy subjects. Conclusion These data suggest that altered IL‐2 production, as well as impaired IL‐2–mediated signaling and proliferative responses, characterize SLE CD4+ T cells. Our data demonstrate the need for caution in designing IL‐2 treatment trials for patients with SLE. Approaches to restore CD4+ T cell sensitivity to IL‐2 should be considered. |
Author | Comte, Denis Tsokos, George C. Kis‐Toth, Katalin Karampetsou, Maria P. Kyttaris, Vasileios C. Yoshida, Nobuya Bradley, Sean J. |
Author_xml | – sequence: 1 givenname: Denis surname: Comte fullname: Comte, Denis organization: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, and Centre Hospitalier Universitaire Vaudois – sequence: 2 givenname: Maria P. surname: Karampetsou fullname: Karampetsou, Maria P. organization: Beth Israel Deaconess Medical Center, Harvard Medical School – sequence: 3 givenname: Katalin surname: Kis‐Toth fullname: Kis‐Toth, Katalin organization: Beth Israel Deaconess Medical Center, Harvard Medical School – sequence: 4 givenname: Nobuya surname: Yoshida fullname: Yoshida, Nobuya organization: Beth Israel Deaconess Medical Center, Harvard Medical School – sequence: 5 givenname: Sean J. surname: Bradley fullname: Bradley, Sean J. organization: Beth Israel Deaconess Medical Center, Harvard Medical School – sequence: 6 givenname: Vasileios C. surname: Kyttaris fullname: Kyttaris, Vasileios C. organization: Beth Israel Deaconess Medical Center, Harvard Medical School – sequence: 7 givenname: George C. surname: Tsokos fullname: Tsokos, George C. email: gtsokos@bidmc.harvard.edu organization: Beth Israel Deaconess Medical Center, Harvard Medical School |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27992687$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkc1u1DAQxyNUREvpgRdAlrjwoW39Eccxt7JsodJKVMsijpHXnlCXxA62Q8mNR-AZeRJctuVQiQpfxqP5zYz-_3lY7DjvoCgeE3xIMKZHKqTDEmNS3iv2KKPVjFPMd27-RJLd4iDGC5yfFLjC_EGxS4WUtKrFXvHtdbDQohUMPqRXaP6mfInWaA5dF9FJ8D06U8mCSxF9sukcfZhigt5qtByHMaJFmNI59Cr5mLMVxME7g868D92EkkeL7_4zOJ9rpy5B6GD8Yt2vHz_po-J-q7oIB9dxv_h4sljP382W79-ezo-XM80kLmfMGM2ralODaUVFCRgtSq0NN4bUtTZYmw2Rim0k0QK3pMLAFC5ZKcqWcEzYfvFiO3d0g5ouVdc1Q7C9ClNDcHPlX5P9a_74l-FnW3gI_usIMTW9jTpboRxkDU1eWUvBGZf_gXJCJeO1yOjTW-iFH4PLqhtKJa5Kyas7qbyWiJpJdkU9uabGTQ_mr5abe2bg-RbQwccYoL1T7tEtVtuUr-1dCsp2d3Vc2g6mf49ujlfrbcdvZLXONQ |
CitedBy_id | crossref_primary_10_1136_annrheumdis_2018_214229 crossref_primary_10_1007_s00103_020_03230_8 crossref_primary_10_1111_1440_1681_12946 crossref_primary_10_1097_BOR_0000000000000924 crossref_primary_10_3389_fimmu_2021_632383 crossref_primary_10_1089_jir_2018_0016 crossref_primary_10_2139_ssrn_3802857 crossref_primary_10_3389_fimmu_2018_01088 crossref_primary_10_1038_s41590_020_0677_6 crossref_primary_10_1016_j_clim_2022_109201 crossref_primary_10_3389_fimmu_2022_1016427 crossref_primary_10_1016_j_jaut_2019_102376 crossref_primary_10_4103_jpgm_JPGM_1270_20 crossref_primary_10_1007_s00281_019_00741_8 crossref_primary_10_1038_nrneph_2017_34 crossref_primary_10_1080_08916934_2019_1693545 crossref_primary_10_1038_s41392_023_01350_6 crossref_primary_10_1038_s41467_020_19918_z crossref_primary_10_1016_j_clim_2018_11_002 crossref_primary_10_3389_fimmu_2022_1075813 crossref_primary_10_1007_s11926_018_0745_1 crossref_primary_10_1016_j_clim_2018_11_001 crossref_primary_10_23868_202110003 crossref_primary_10_3389_fimmu_2023_1305590 crossref_primary_10_4103_injr_injr_48_22 crossref_primary_10_3389_fimmu_2021_667342 crossref_primary_10_1038_s41584_021_00707_x crossref_primary_10_3390_biomedicines8120559 crossref_primary_10_1016_j_molmed_2022_04_010 crossref_primary_10_1038_nrd_2018_148 crossref_primary_10_1136_ard_2022_222501 crossref_primary_10_1016_j_berh_2017_09_007 crossref_primary_10_1177_0961203318760993 crossref_primary_10_1097_BOR_0000000000000575 crossref_primary_10_1177_0961203317722848 crossref_primary_10_1016_j_clim_2018_08_013 crossref_primary_10_1016_j_jaci_2023_12_023 crossref_primary_10_1097_BOR_0000000000000772 crossref_primary_10_1016_j_clim_2017_06_004 crossref_primary_10_1016_j_coi_2019_07_003 crossref_primary_10_1016_j_jaci_2018_10_015 crossref_primary_10_1080_25785826_2019_1628466 crossref_primary_10_2174_1871530323666230915112642 crossref_primary_10_3389_fimmu_2022_938556 |
Cites_doi | 10.1177/0961203314556139 10.1038/nm.4148 10.1136/annrheumdis-2014-206506 10.1056/NEJMra1100359 10.1136/annrheumdis-2015-207776 10.1155/2011/432595 10.1002/art.1780350606 10.1073/pnas.1605081113 10.1089/jir.2011.0029 10.1007/s10875-008-9235-y 10.1002/art.1780251101 10.1002/cyto.a.21015 10.1016/j.immuni.2013.01.004 10.1038/sj.embor.7401099 10.1038/44385 |
ContentType | Journal Article |
Copyright | 2016, American College of Rheumatology 2016, American College of Rheumatology. 2017, American College of Rheumatology |
Copyright_xml | – notice: 2016, American College of Rheumatology – notice: 2016, American College of Rheumatology. – notice: 2017, American College of Rheumatology |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7QP 7T5 7TM 7U7 C1K H94 K9. 7X8 ADTOC UNPAY |
DOI | 10.1002/art.40014 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Immunology Abstracts Nucleic Acids Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Toxicology Abstracts Bacteriology Abstracts (Microbiology B) Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Calcium & Calcified Tissue Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Toxicology Abstracts AIDS and Cancer Research Abstracts MEDLINE MEDLINE - Academic Toxicology Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2326-5205 |
EndPage | 813 |
ExternalDocumentID | 10.1002/art.40014 4321261035 27992687 10_1002_art_40014 ART40014 |
Genre | shortCommunication Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIH funderid: P01‐AI‐065687, R01‐AI‐42269, and R37‐AI‐49954 – fundername: SICPA Foundation – fundername: NIAID NIH HHS grantid: R01 AI042269 – fundername: NIAID NIH HHS grantid: P01 AI065687 – fundername: NIAID NIH HHS grantid: R37 AI049954 |
GroupedDBID | 0R~ 1OC 33P 3SF 4.4 52O 52U 52V 53G 5VS AAESR AAEVG AAFWJ AAHQN AAIPD AAMMB AAMNL AANHP AANLZ AAQQT AASGY AAWTL AAXRX AAYCA AAZKR ABCUV ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACFBH ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACRPL ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHMBA AIACR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZFZN AZVAB BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 DCZOG DIK DRFUL DRMAN DRSTM EBS EJD EMOBN EX3 F00 FUBAC G-S G.N GODZA HGLYW KBYEO LATKE LEEKS LH4 LITHE LOXES LUTES LW6 LYRES MEWTI MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM NF~ O66 O9- OVD P2W PQQKQ QB0 ROL SUPJJ TEORI V9Y WBKPD WHWMO WIH WIJ WIK WOHZO WVDHM WXSBR AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7QP 7T5 7TM 7U7 C1K H94 K9. 7X8 ADTOC UNPAY |
ID | FETCH-LOGICAL-c3904-3ddc566b8edf7621edc74ccd5dd188cd0cdb19a3b91c70f160e3a043474f15013 |
IEDL.DBID | UNPAY |
ISSN | 2326-5191 2326-5205 |
IngestDate | Wed Oct 01 15:24:46 EDT 2025 Wed Oct 01 15:07:14 EDT 2025 Fri Jul 11 05:15:37 EDT 2025 Fri Jul 25 12:07:15 EDT 2025 Sun Jul 13 05:37:41 EDT 2025 Mon Jul 21 06:05:22 EDT 2025 Wed Oct 01 01:39:43 EDT 2025 Thu Apr 24 23:09:43 EDT 2025 Sun Sep 21 06:14:56 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2016, American College of Rheumatology. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3904-3ddc566b8edf7621edc74ccd5dd188cd0cdb19a3b91c70f160e3a043474f15013 |
Notes | Drs. Comte and Karampetsou contributed equally to this work. Supported by the NIH (grants P01‐AI‐065687, R01‐AI‐42269, and R37‐AI‐49954 to Dr. Tsokos) and the SICPA Foundation (grant to Dr. Comte). ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.40014 |
PMID | 27992687 |
PQID | 1881783937 |
PQPubID | 946334 |
PageCount | 6 |
ParticipantIDs | unpaywall_primary_10_1002_art_40014 proquest_miscellaneous_1888975359 proquest_miscellaneous_1851293587 proquest_journals_2290649567 proquest_journals_1881783937 pubmed_primary_27992687 crossref_primary_10_1002_art_40014 crossref_citationtrail_10_1002_art_40014 wiley_primary_10_1002_art_40014_ART40014 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | April 2017 |
PublicationDateYYYYMMDD | 2017-04-01 |
PublicationDate_xml | – month: 04 year: 2017 text: April 2017 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Atlanta |
PublicationTitle | Arthritis & rheumatology (Hoboken, N.J.) |
PublicationTitleAlternate | Arthritis Rheumatol |
PublicationYear | 2017 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2015; 24 2011; 2011 1982; 25 2013; 38 2010 2015; 74 2008; 28 2007; 8 2011; 31 2016; 113 2016; 75 1992; 35 2011; 79 1999; 401 2011; 365 2016; 22 e_1_2_6_10_1 Lieberman LA (e_1_2_6_7_1) 2010 e_1_2_6_9_1 e_1_2_6_8_1 e_1_2_6_5_1 e_1_2_6_4_1 e_1_2_6_6_1 e_1_2_6_13_1 e_1_2_6_14_1 e_1_2_6_3_1 e_1_2_6_11_1 e_1_2_6_2_1 e_1_2_6_12_1 e_1_2_6_17_1 e_1_2_6_15_1 e_1_2_6_16_1 22129255 - N Engl J Med. 2011 Dec 1;365(22):2110-21 21265010 - Cytometry A. 2011 Feb;79(2):167-74 18059313 - EMBO Rep. 2007 Dec;8(12):1142-8 20625413 - J Biomed Biotechnol. 2010;2010:740619 10537110 - Nature. 1999 Oct 14;401(6754):708-12 25609413 - Ann Rheum Dis. 2015 Apr;74(4):791-2 18726679 - J Clin Immunol. 2008 Nov;28(6):635-9 22028588 - J Biomed Biotechnol. 2011;2011:432595 27482100 - Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):9321-6 26324847 - Ann Rheum Dis. 2016 Jul;75(7):1407-15 25801878 - Lupus. 2015 Apr;24(4-5):351-63 23352221 - Immunity. 2013 Jan 24;38(1):13-25 21877904 - J Interferon Cytokine Res. 2011 Oct;31(10):769-79 27500725 - Nat Med. 2016 Sep;22(9):991-3 7138600 - Arthritis Rheum. 1982 Nov;25(11):1271-7 |
References_xml | – volume: 401 start-page: 708 year: 1999 end-page: 12 article-title: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions publication-title: Nature – volume: 74 start-page: 791 year: 2015 end-page: 2 article-title: Rapid induction of clinical remission by low‐dose interleukin‐2 in a patient with refractory SLE publication-title: Ann Rheum Dis – volume: 2011 start-page: 432595 year: 2011 article-title: Inflammatory cytokines in systemic lupus erythematosus publication-title: J Biomed Biotechnol – start-page: 740619 year: 2010 article-title: The IL‐2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity publication-title: J Biomed Biotechnol – volume: 75 start-page: 1407 year: 2016 end-page: 15 article-title: Low‐dose interleukin‐2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus publication-title: Ann Rheum Dis – volume: 25 start-page: 1271 year: 1982 end-page: 7 article-title: The 1982 revised criteria for the classification of systemic lupus erythematosus publication-title: Arthritis Rheum – volume: 35 start-page: 630 year: 1992 end-page: 40 article-title: and the Committee on the Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients publication-title: Arthritis Rheum – volume: 365 start-page: 2110 year: 2011 end-page: 21 article-title: Systemic lupus erythematosus publication-title: N Engl J Med – volume: 28 start-page: 635 year: 2008 end-page: 9 article-title: IL‐2 family of cytokines in T regulatory cell development and homeostasis publication-title: J Clin Immunol – volume: 31 start-page: 769 year: 2011 end-page: 79 article-title: The dysregulation of cytokine networks in systemic lupus erythematosus publication-title: J Interferon Cytokine Res – volume: 79 start-page: 167 year: 2011 end-page: 74 article-title: SPICE: exploration and analysis of post‐cytometric complex multivariate datasets publication-title: Cytometry A – volume: 113 start-page: 9321 year: 2016 end-page: 6 article-title: Engagement of SLAMF3 enhances CD4 T‐cell sensitivity to IL‐2 and favors regulatory T‐cell polarization in systemic lupus erythematosus publication-title: Proc Natl Acad Sci U S A – volume: 22 start-page: 991 year: 2016 end-page: 3 article-title: Low‐dose interleukin‐2 treatment selectively modulates CD4 T cell subsets in patients with systemic lupus erythematosus publication-title: Nat Med – volume: 8 start-page: 1142 year: 2007 end-page: 8 article-title: Interleukin 2: from immunostimulation to immunoregulation and back again publication-title: EMBO Rep – volume: 24 start-page: 351 year: 2015 end-page: 63 article-title: T cells as a therapeutic target in SLE publication-title: Lupus – volume: 38 start-page: 13 year: 2013 end-page: 25 article-title: Interleukin‐2 at the crossroads of effector responses, tolerance, and immunotherapy publication-title: Immunity – ident: e_1_2_6_3_1 doi: 10.1177/0961203314556139 – ident: e_1_2_6_8_1 doi: 10.1038/nm.4148 – ident: e_1_2_6_9_1 doi: 10.1136/annrheumdis-2014-206506 – start-page: 740619 year: 2010 ident: e_1_2_6_7_1 article-title: The IL‐2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity publication-title: J Biomed Biotechnol – ident: e_1_2_6_2_1 doi: 10.1056/NEJMra1100359 – ident: e_1_2_6_10_1 doi: 10.1136/annrheumdis-2015-207776 – ident: e_1_2_6_11_1 doi: 10.1155/2011/432595 – ident: e_1_2_6_14_1 doi: 10.1002/art.1780350606 – ident: e_1_2_6_17_1 doi: 10.1073/pnas.1605081113 – ident: e_1_2_6_12_1 doi: 10.1089/jir.2011.0029 – ident: e_1_2_6_5_1 doi: 10.1007/s10875-008-9235-y – ident: e_1_2_6_13_1 doi: 10.1002/art.1780251101 – ident: e_1_2_6_15_1 doi: 10.1002/cyto.a.21015 – ident: e_1_2_6_6_1 doi: 10.1016/j.immuni.2013.01.004 – ident: e_1_2_6_4_1 doi: 10.1038/sj.embor.7401099 – ident: e_1_2_6_16_1 doi: 10.1038/44385 – reference: 18726679 - J Clin Immunol. 2008 Nov;28(6):635-9 – reference: 10537110 - Nature. 1999 Oct 14;401(6754):708-12 – reference: 22028588 - J Biomed Biotechnol. 2011;2011:432595 – reference: 25609413 - Ann Rheum Dis. 2015 Apr;74(4):791-2 – reference: 22129255 - N Engl J Med. 2011 Dec 1;365(22):2110-21 – reference: 25801878 - Lupus. 2015 Apr;24(4-5):351-63 – reference: 23352221 - Immunity. 2013 Jan 24;38(1):13-25 – reference: 27500725 - Nat Med. 2016 Sep;22(9):991-3 – reference: 21877904 - J Interferon Cytokine Res. 2011 Oct;31(10):769-79 – reference: 26324847 - Ann Rheum Dis. 2016 Jul;75(7):1407-15 – reference: 7138600 - Arthritis Rheum. 1982 Nov;25(11):1271-7 – reference: 21265010 - Cytometry A. 2011 Feb;79(2):167-74 – reference: 27482100 - Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):9321-6 – reference: 18059313 - EMBO Rep. 2007 Dec;8(12):1142-8 – reference: 20625413 - J Biomed Biotechnol. 2010;2010:740619 |
SSID | ssj0000970605 |
Score | 2.4332016 |
Snippet | Objective
Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus‐prone mice and contributes to... Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus-prone mice and contributes to immune... Objective Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus-prone mice and contributes to... ObjectiveImbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus‐prone mice and contributes to... |
SourceID | unpaywall proquest pubmed crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 808 |
SubjectTerms | 12-O-Tetradecanoylphorbol-13-acetate Acetic acid CD28 antigen CD3 antigen CD4 antigen CD4-Positive T-Lymphocytes - immunology Cell differentiation Cell proliferation Cells, Cultured Chronic conditions Clinical trials Cytokines Dilution Humans Interferon Interferon-gamma - biosynthesis Interleukin-17 - biosynthesis Interleukin-2 - biosynthesis Interleukin-2 - therapeutic use Interleukin-4 - biosynthesis Interleukins Ionomycin Lupus Lupus Erythematosus, Systemic - drug therapy Lupus Erythematosus, Systemic - immunology Lymphocytes Lymphocytes T Phosphorylation Production methods Signal transduction Signaling Stimulation Systemic lupus erythematosus γ-Interferon |
Title | Brief Report: CD4+ T Cells From Patients With Systemic Lupus Erythematosus Respond Poorly to Exogenous Interleukin‐2 |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fart.40014 https://www.ncbi.nlm.nih.gov/pubmed/27992687 https://www.proquest.com/docview/1881783937 https://www.proquest.com/docview/2290649567 https://www.proquest.com/docview/1851293587 https://www.proquest.com/docview/1888975359 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.40014 |
UnpaywallVersion | publishedVersion |
Volume | 69 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2326-5205 dateEnd: 20241003 omitProxy: true ssIdentifier: ssj0000970605 issn: 2326-5205 databaseCode: DIK dateStart: 19990101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLagk7g8cL8UxmQuD5NQSnyJk_A2Sqtx2VShVYynkNiOqBaSqk2A8sRP4DfySzi204jBmJB4c-Rjy3bOsb_jY39G6BGRLBWK5F6QcuFxBX5KGubUYxKwMzhvTGqz37G3L3an_OVhcNi-c2ruwjh-iG7DzViGna-Ngc9V7ub5NrpPn8DoDrhB-WfRhjARph7amO5Pdt7ZJ-Wo8ACfkC5N_WDNLfRr2eMr0h8w8yI635TzdPU5LYrjCNYuQePL6P268e7kydGgqbOB_Pobr-N_9O4KutTCU7zj9OkqOqPLa-jcXhuAv44-PQPXOscOtj_Fw-f8MT7AQ10USzxeVB_xxPG0LvHbWf0BOz70mcSvm3mzxKPFypHEVkv4emOP5yo8qapFscJ1hUdfKscZi-1GZaGbo1n549t3egNNx6OD4a7XPt3gSRabWItSEoBiFmmVw3RLtJIhl1IFSpEoksqXKiNxyrKYyNDPifA1S33OeMhzgKiE3US9sir1bYQjmgVCAwyNpeQyyNJcxJqKMJOSRXnG-mh7_fsS2fKam-c1isQxMtMExjGx49hHDzrRuSPzOEloc60DSWvPywQaTcLIkAeemG1J842rCdn3u2wwVBN9SUsNAwdVWGwVRKfKRJG56RzEfXTLqV_XUBrGMRWm9MNOH0_rxbZVr79LJOAw2cSdf6rwLrpADaKxh5Y2Ua9eNPoe4LE62wJP5MWrrdbyfgLJ8jS0 |
linkProvider | Unpaywall |
linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLagk2A8cB8UBjKXh0koJb7ESXgbpdWE2FShVWxPIbEdUS0kVZsA5YmfwG_kl3BspxGDMSHx5sjHlu2cY3_Hx_6M0FMiWSoUyb0g5cLjCvyUNMypxyRgZ3DemNRmv2P_QOxN-euj4Kh959TchXH8EN2Gm7EMO18bA5-r3M3zbXSfPofRHXCD8i-iDWEiTD20MT2Y7B7bJ-Wo8ACfkC5N_WDNLfRr2dMr0h8w8wq63JTzdPU5LYrTCNYuQeNr6P268e7kycmgqbOB_Pobr-N_9O46utrCU7zr9OkGuqDLm-jSfhuAv4U-vQTXOscOtr_Aw1f8GT7EQ10USzxeVB_xxPG0LvG7Wf0BOz70mcRvmnmzxKPFypHEVkv4emuP5yo8qapFscJ1hUdfKscZi-1GZaGbk1n549t3ehtNx6PD4Z7XPt3gSRabWItSEoBiFmmVw3RLtJIhl1IFSpEoksqXKiNxyrKYyNDPifA1S33OeMhzgKiEbaFeWZX6LsIRzQKhAYbGUnIZZGkuYk1FmEnJojxjfbSz_n2JbHnNzfMaReIYmWkC45jYceyjx53o3JF5nCW0vdaBpLXnZQKNJmFkyAPPzLak-cbVhOxHXTYYqom-pKWGgYMqLLYKonNlosjcdA7iPrrj1K9rKA3jmApT-kmnj-f1Yseq198lEnCYbOLeP1V4H21Sg2jsoaVt1KsXjX4AeKzOHrY29xOTcDO7 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Brief+Report%3A+CD4%2B+T+Cells+From+Patients+With+Systemic+Lupus+Erythematosus+Respond+Poorly+to+Exogenous+Interleukin-2&rft.jtitle=Arthritis+%26+rheumatology+%28Hoboken%2C+N.J.%29&rft.au=Comte%2C+Denis&rft.au=Karampetsou%2C+Maria+P&rft.au=Kis-Toth%2C+Katalin&rft.au=Yoshida%2C+Nobuya&rft.date=2017-04-01&rft.issn=2326-5191&rft.eissn=2326-5205&rft.volume=69&rft.issue=4&rft.spage=808&rft.epage=813&rft_id=info:doi/10.1002%2Fart.40014&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2326-5191&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2326-5191&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2326-5191&client=summon |